Prof Mike McGuckin
Acting Dean
Faculty of Medicine, Dentistry and Health Sciences
298 Scholarly works
4 Projects
HIGHLIGHTS
2025
Journal article
Harnessing IL-22 for metabolic health: promise and pitfalls
DOI: 10.1016/j.molmed.2024.10.0162024
Journal article
Pancreatic beta-cell IL-22 receptor deficiency induces age-dependent dysregulation of insulin biosynthesis and systemic glucose homeostasis
DOI: 10.1038/s41467-024-48320-22024
Journal article
Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis
DOI: 10.1038/s41467-024-48317-x2023
Journal article
Interleukin-22 suppresses major histocompatibility complex II in mucosal epithelial cells
DOI: 10.1084/jem.202301062020
Research Contracts
Marc
2019
Research contracts (non-grants)
Melbourne Genomics Health Alliance
2019
Research Grant
Targeting Muc13 to Sensitise Colorectal Cancer to Therapy
RECENT SCHOLARLY WORKS
2023
Journal article
MUC13 Cell Surface Mucin Limits Salmonella Typhimurium Infection by Protecting the Mucosal Epithelial Barrier
DOI: 10.1016/j.jcmgh.2023.08.0112022
Conference Proceedings
A novel role for interleukin-22 signaling in modulating mucosal epithelial cell antigen presentation machinery to control disease
2022
Journal article
Building a case for pancreas and liver targeted intereukin-22 therapy in fatty liver disease
DOI: 10.1016/s0168-8278(22)00756-52022
Journal article
Targeted IL-22 Improves Glucose Tolerance and Reduces Hepatic Steatosis and Hepatic Fibrosis in Murine Models of Diabetes and Liver Disease
DOI: 10.2337/db22-119-LB2022
Journal article
89: BUILDING A CASE FOR LIVER AND PANCREAS TARGETED INTERLEUKIN-22 THERAPY FOR USE IN NON-ALCOHOLIC FATTY LIVER DISEASE
DOI: 10.1016/s0016-5085(22)60035-02022
Conference Proceedings
BUILDING A CASE FOR LIVER AND PANCREAS TARGETED INTERLEUKIN-22 THERAPY FOR USE IN NON-ALCOHOLIC FATTY LIVER DISEASE
RECENT PROJECTS
2020
Research Grant
Liver Targeted Interleukin-22 for the Treatment of Non-Alcoholic Steatohepatitis